APPENDIX B

VERSION WITH MARKINGS TO SHOW CHANGES MADE

37 C.F.R. § 1.121(b)(iii) AND (c)(ii)

CLAIMS:

3. The use according to [any preceding claim] claim 1, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

4. The use according to [claims 1 or 2] claim 1, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

5. The use according to [claims 1 or 2] claim 1, wherein the chemokine receptor antagonist is Met-RANTES.

6. The use according to [any preceding claim] claim 1, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

7. The use according to [any preceding claim] claim 1, wherein the cyclosporin is cyclosporin A.

8. The use according to [any preceding claim] claim 1, for treating or preventing renal allograft transplantation.

11. The pharmaceutical composition according to [claim 9 or 10] claim 9, wherein the chemokine receptor antagonist is an amino-terminally truncated chemokine.

12. The pharmaceutical composition according to [claims 9 or 10] claim 9, wherein the chemokine receptor antagonist is an amino-terminally extended RANTES.

13. The pharmaceutical composition according to [claims 9 or 10] claim 9, wherein the chemokine receptor antagonist is Met-RANTES.

14. The pharmaceutical composition according to [any of claims 9 to 13] claim 9, wherein the cyclosporin is selected among cyclosporin A as well as metabolites or synthetic analogues thereof.

15. The pharmaceutical composition according to [any of claims 10 to 14] claim 10, wherein the cyclosporin is cyclosporin A.

16. The pharmaceutical composition according to [any of claims 9 to 15] claim 9, for treating or preventing renal allograft transplantation.